Skip to main content
Industry News
Celularity's IND cleared to assess glioblastoma multiforme therapy

Celularity has gained FDA clearance for its investigational new drug application for its natural killer cell therapy CYNK-001 designed to treat glioblastoma multiforme. The company announced plans to launch their first-in-human clinical trial in the US to test CYNK-001 in patients with relapsed glioblastoma multiforme.

Full Story: